Abstract
Psoriasis is a chronic skin disease of unknown aetiology but increasing evidence suggests that cutaneous angiogenesis plays an important role. Vascular endothelial growth factor (VEGF) is one of the pro-angiogenic cytokines which is related to the pathogenesis of psoriasis. Our study evaluated the influence of imiquimod (IMQ) on VEGF in IMQ-induced mouse model.
Balb/c female mice (n=16) 8-12 weeks of age were randomly divided into an experimental group (5% IMQ cream) and the control group (Vaseline cream). Serum levels of circulating VEGF-A were quantified by enzyme-linked immunosorbent assay. VEGF protein expression in tested skin was measured by western blotting and immunohistochemical staining.
The tested skin in the experimental group expressed higher levels of VEGF protein than in the control group (p=0.012); immunohistochemical staining revealed that the cells over-expressing VEGF localized predominantly in the epidermis and vascular endothelium. Circulating VEGF-A levels showed no significant difference between the experimental and control groups (p=0.445).
The IMQ-induced mouse psoriatic model showed an upregulation of VEGF in the skin lesions mimicking human psoriasis but the circulating VEGF-A levels showed no difference. This model may be useful to investigate the role of angiogenesis in psoriasis.
Keywords: Imiquimod, mouse, model, psoriasis, vascular endothelial growth factor.
Current Vascular Pharmacology
Title:Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model
Volume: 14 Issue: 3
Author(s): Hui-Hui Wu, Wen-Lin Xie, Yu-Kun Zhao, Juan-Hua Liu and Di-Qing Luo
Affiliation:
Keywords: Imiquimod, mouse, model, psoriasis, vascular endothelial growth factor.
Abstract: Psoriasis is a chronic skin disease of unknown aetiology but increasing evidence suggests that cutaneous angiogenesis plays an important role. Vascular endothelial growth factor (VEGF) is one of the pro-angiogenic cytokines which is related to the pathogenesis of psoriasis. Our study evaluated the influence of imiquimod (IMQ) on VEGF in IMQ-induced mouse model.
Balb/c female mice (n=16) 8-12 weeks of age were randomly divided into an experimental group (5% IMQ cream) and the control group (Vaseline cream). Serum levels of circulating VEGF-A were quantified by enzyme-linked immunosorbent assay. VEGF protein expression in tested skin was measured by western blotting and immunohistochemical staining.
The tested skin in the experimental group expressed higher levels of VEGF protein than in the control group (p=0.012); immunohistochemical staining revealed that the cells over-expressing VEGF localized predominantly in the epidermis and vascular endothelium. Circulating VEGF-A levels showed no significant difference between the experimental and control groups (p=0.445).
The IMQ-induced mouse psoriatic model showed an upregulation of VEGF in the skin lesions mimicking human psoriasis but the circulating VEGF-A levels showed no difference. This model may be useful to investigate the role of angiogenesis in psoriasis.
Export Options
About this article
Cite this article as:
Wu Hui-Hui, Xie Wen-Lin, Zhao Yu-Kun, Liu Juan-Hua and Luo Di-Qing, Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model, Current Vascular Pharmacology 2016; 14 (3) . https://dx.doi.org/10.2174/1570161114666160106151837
DOI https://dx.doi.org/10.2174/1570161114666160106151837 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct
Current Cancer Therapy Reviews Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry Reprogramming Cancer Cells in Endocrine-Related Tumors: Open Issues
Current Medicinal Chemistry Drug-Targeting Strategies for Prostate Cancer
Current Pharmaceutical Design Chartreusin, Elsamicin A and Related Anti-Cancer Antibiotics
Current Medicinal Chemistry - Anti-Cancer Agents The p53-p66Shc Apoptotic Pathway is Dispensable for Tumor Suppression whereas the p66Shc-generated Oxidative Stress Initiates Tumorigenesis
Current Pharmaceutical Design KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives
Current Molecular Medicine MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types
Current Cancer Drug Targets Fabrication and Evaluation of Glabridin Tip-loaded Dissolving Microneedles
Current Drug Delivery Use of Cytokines in Cancer Vaccines/Immunotherapy: Recent Developments Improve Survival Rates for Patients with Metastatic Malignancy
Current Pharmaceutical Design Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature
Current Drug Safety Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry